胃肠动力障碍性疾病的发病机制认识及诊治进展

税典奎; 谢胜

doi:10.3969/j.issn.1671-038X.2013.01.019

胃肠动力障碍性疾病的发病机制认识及诊治进展

税典奎,
谢胜

- 柳州市中医院脾胃病科, 广西柳州 545001

详细信息

中图分类号: R723.1

收稿日期: 2012-10-30

Received Date: 30 October 2012

摘要

- 胃肠动力障碍 /
- 发病机制 /
- 诊治

HTML全文

参考文献(43)

[1]	HALDER S I, IOCKE G R, SCHLECK C D.Naturalhistory of functional gastr0intestinal disorders;a l2-year longitudinal population based study[J].Gastroen-terology, 2007, 133:799-807.
[2]	DANIEL E E.Communication between interstitial ce-lls of Cajal and gastrointestinal smoothmuscle[J].Neu-rogastroenterol Motil, 2004, 16 (Suppl 1) :118-122.
[3]	李春穴, 童卫东, 刘宝华, 等.Cajal间质细胞的分离、培养方法探讨[J].消化外科, 2004, 3 (4) :267-269.
[4]	SHAFIK A, SHAFIK A A, EI-SIBAI O, et al.Electricactivity of thecolon in subjects with constipation due tototal colonic inertia:an electrophysiologic study[J].Arch Surg, 2003, 138:7-11.
[5]	LEE J I, PARK H, KAMM M A, et al.Decreased den-sity of interstitial cells ofCajal and neuronal cells in pa-tientswith slowtransit constipation and acquiredmega-colon[J].J Gastroenterol Hepatol, 2005, 20:1292-1298.
[6]	LIN Z, FORSTER J, SAROSIEK I, et al.Treatment ofgastroparesis with electrical stimulation[J].Dig DisSci, 2003, 48:837-848.
[7]	STREUTKER C J, HUIZINGA J D, DRIMAN D K, etal.Interstitial cells of Cajal in health and disease.PartI:normal ICC structure and function with associated-motility disorders[J].Histopathology, 2007, 50:176-189.
[8]	JONSSON B H, HELLSTROM P M.Motilin and neu-ropeptide Y-like immunoreactivity in apsychophysio-logical stress experiment on patients with funcionaldyspepsia[J].Integr Physiol Behav Sci, 2000, 35:256-265.
[9]	FEIGHNER S D, TAN C P, MCKEE K K, etal.Receptor for motilin identified in the human gastro-intestinal system[J].Science, 1999, 284:2184-2188.
[10]	陈天娥, 王秀琴.大鼠脾气虚胃溃疡证病结合模型胃肠黏膜局部免疫神经内分泌网络的变化[J].解剖学报, 2003, 34 (4) :441-444.
[11]	陆英杰, 连至诚.胃肠激素对胃肠动力的影响[J].中国热带医学, 2005, 5 (6) :1338-1339.
[12]	邹百仓, 董蕾.5-羟色胺7受体与功能性胃肠病[J].国际消化病杂志, 2007, 27 (2) :76-77.
[13]	DAVID R, THOMAS D R, HAGAN J J.5-HT7Re-ceptors[J].Cur Drug Tarqets CNS Neurol Disord, 2004, 3:81-90.
[14]	MORO E, CREMA F, DEPONTI F, et al.Triptans andgastric accommodation:pharmacological and therapeu-tic aspects[J].Dig Liver Dis, 2004, 36:85-85.
[15]	王颖, 佟静, 王炳元.乙醇对大鼠胃底5-羟色胺2B受体表达水平影响的研究[J].中国医科大学学报, 2007, 36 (1) :55-55.
[16]	WOUTERS M M, GIBBONS S J, ROEDER J L, et al.Exogenous serotonin regulates proliferation of intersti-tial cells of Cajal in mouse jejunum through 5-HT2Breceptors[J].Gastroenterology, 2007, 133:897-906.
[17]	LI T J, YU B P, DONG W G, et al.Ovarian hormonemodulates 5-hydroxytryptamine 3receptors mRNA ex-pression in rat colon with restraint stressinduced boweldysfunction[J].World J Gastroenterol, 2004, 10:2723-2723.
[18]	GERSHON M D, LIU M T.Serotonin and neuropro-tection in functional bowel disorders[J].Neurogastro-enterol Motil, 2007, 19:19-19.
[19]	DUMAN EN, KESIM M, KADIOGLU M, et al.Possi-ble involvement of opioidergic and serotonergic mecha-nisms in antinociceptive effect of paroxetine in acutepain[J].J Pharmacol Sci, 2004, 94:161-165.
[20]	TONINI M, VICINI R, CERVIO E, et al.5-HT7re-ceptors modulate peristalsis and accommodation in theguinea pig ileum[J].Gastroenterology, 2005, 129:1557-1566.
[21]	T HURMANN P A.Adverse drugs reactions:diagnosi-sand assessment[J].Pathology, 2005, 8:102-102.
[22]	IOTSCH J, SKARKE C, SCHNEIDER A, et al.The 5-hydroxytryptamin 4receptor agonist mosepride dosesnot antagonize morphine-induced respimtory depres-sion[J].Clin Phammcol Ther, 2005, 78:278-278.
[23]	ANDRESEN V, HOLLERBAEH S.Reassossing thebenefits and risks of alcestron:what its place in thetreatment of irritable bowel syndrome[J].Drug Saf, 2004, 27:283-292.
[24]	CHEY W D, CASH B D.Cilansetron:A new seroton-ergic agent for the irritable bowel syndrome with diar-rhoea[J].Expert Opin Investig Drugs, 2005, 14:185-185.
[25]	CAMILLEN M, MCKINZIE S, FOX J, et al.Effect ofrenzap ride on transit in constipation-predominant irri-table bowel syndrome[J].Clin Gastroenterol Hepatol, 2004, 2:895-895.
[26]	胡建英.胃肠动力障碍性疾病发病机制及其药物研究概况[J].海峡药学, 2008, 20 (11) :111-111.
[27]	衣兰娟, 田琳, 梁宁霞, 等.促结肠动力中药筛选及其机制[J].世界华人消化杂志, 2006, 14 (32) :3095-3095.
[28]	朱金照, 冷恩仁, 陈东风.15味中药促胃肠动力作用的筛选研究[J].第三军医大学学报, 2000, 22 (5) :436-438.
[29]	郝庆, 李岩, 张恒军.柴胡枳实促胃肠动力作用机制的实验研究[J].辽宁药物与临床, 2002, 5 (2) :66-66.
[30]	袁静.中医药对胃肠动力异常研究进展[J].中国中医急诊, 2011, 20 (3) :440-441.
[31]	王瑞萍, 唐方.藿香与陈皮不同比例合煎水提物对大鼠胃肠运动的影响[J].中国实验方剂学杂志, 2010, 16 (15) :98-100.
[32]	王少根, 陈侠英, 王立基, 等.党参对小鼠Ⅲ度烫伤早期胃肠动力的影响[J].安徽中医学院学报, 2007, 18 (6) :50-50.
[33]	孙维峰, 徐伟, 王小春, 等.升降汤对小鼠胃肠蠕动及胃肠激素的影响[J].安徽中医学院学报, 2002;21 (1) :45-46.
[34]	窦丹波, 黄英武, 王松坡.枳实消痞丸对大鼠上消化道CCK及CCKA受体mRNA表达的影响[J].世界华人消化杂志, 2009, 10 (8) :927-930.
[35]	寻庆英, 杨德治, 窦国祥, 等.通腑汤对胃肠动力障碍大鼠小肠肌间神经丛中5-HT、SP和VIP含量的影响[J].东南大学学报:医学版, 2007, 2l (3) :221-221.
[36]	彭向东, 黄玉玺.香砂六君子丸对功能性消化不良患者胃电图及胃泌素的影响[J].深圳中西医结合杂志, 2006, 11 (1) :20-23.
[37]	张燕, 刘俊田, 沈舒文, 等.胃肠舒泰颗粒对大鼠胃泌素含量及小鼠胃肠运动功能的影响[J].中国中西医结合消化杂志, 2002, 10 (6) :332-336.
[38]	税典奎, 谢胜.旋覆代赭汤对胃动力低下大鼠胃窦组织中5-羟色胺胺前体和脱羧细胞的影响[J].中国中西医结合消化杂志, 2010, 18 (2) :312-315.
[39]	谢胜, 税典奎.旋覆代赭汤对胃动力低下大鼠血液及组织中GAS、SP及SS的影响[J].中医药学报, 2010, 38 (5) :65-68.
[40]	税典奎, 谢胜.旋覆代赭汤对胃动力低下大鼠血液及组织中胃动素, 胃泌素及血管活性肠肽含量的影响[J].中国实验方剂学杂志, 2011, 17 (11) :161-164.
[41]	刘守志, 盛宝军.疏肝理气活血法治疗功能性消化不良60例临床观察[J].安徽中医临床杂志, 2008, 14 (5) :367-367.
[42]	王继勇, 郑泽棠, 池建安, 等.益气通腑法促进腹部手术后胃肠动力恢复的临床研究[J].新中医, 2008, 40 (7) :44-45.
[43]	郭金勇, 刘孟安, 王连文, 等.中药胃肠舒片对胃肠动力障碍大鼠血浆胃动素、P物质和生长抑素的影响[J].滨州医学院学报, 2011, 34 (1) :1-3.

施引文献

资源附件(0)

访问统计

计量

文章访问数: 256
PDF下载数: 766
施引文献: 0

胃肠动力障碍性疾病的发病机制认识及诊治进展

计量

目录

{{newsColumn.name}}

胃肠动力障碍性疾病的发病机制认识及诊治进展

计量

出版历程

目录

{{newsColumn.name}}